Atossa Therapeutics (NASDAQ:ATOS) Upgraded by Craig Hallum to "Strong-Buy" Rating

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) was upgraded by equities researchers at Craig Hallum to a "strong-buy" rating in a note issued to investors on Thursday, MarketBeat reports. The brokerage presently has a $4.00 price target on the stock. Craig Hallum's target price points to a potential upside of 344.40% from the company's current price.

A number of other analysts also recently commented on ATOS. Ascendiant Capital Markets increased their price objective on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a "buy" rating in a report on Monday, April 21st. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $6.17.

Atossa Therapeutics Stock Up 4.7%

Shares of ATOS stock traded up $0.04 during mid-day trading on Thursday, hitting $0.90. 644,942 shares of the stock were exchanged, compared to its average volume of 777,998. The firm has a fifty day moving average of $0.77 and a 200 day moving average of $0.87. Atossa Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.66. The company has a market cap of $116.27 million, a PE ratio of -4.09 and a beta of 0.92.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities analysts predict that Atossa Therapeutics will post -0.22 EPS for the current year.

Institutional Trading of Atossa Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Gallagher Capital Advisors LLC acquired a new stake in shares of Atossa Therapeutics during the 4th quarter worth approximately $25,000. Millennium Management LLC acquired a new stake in shares of Atossa Therapeutics during the 4th quarter worth approximately $28,000. Two Sigma Advisers LP increased its holdings in shares of Atossa Therapeutics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after buying an additional 28,900 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Atossa Therapeutics by 224.0% during the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company's stock worth $59,000 after buying an additional 43,449 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Atossa Therapeutics by 30.7% during the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares during the period. Institutional investors and hedge funds own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.